Abstract：
Recently, the European Respiratory Society (ERS) developed new international guidelines for the treatment of sarcoidosis. This manuscript attempts to distill the ERS Sarcoidosis Treatment Guidelines to a manageable format that can be easily used by practitioners.
The ERS Sarcoidosis Treatment Guidelines addressed the treatment of pulmonary, skin, cardiac, neurologic, and sarcoidosis-associated fatigue. Therapeutic drug dosing and treatment algorithms for these conditions were also addressed. Glucocorticoids were the initial recommended treatment for these conditions except for sarcoidosis-associated fatigue where a pulmonary exercise program or a neurostimulant was initially suggested. Because of the risk of glucocorticoid side-effects, the Guidelines recommended early consideration of glucocorticoid-sparing therapy including certain antimetabolites and two specific tumor necrosis alpha antagonists: infliximab and adalimumab.
The ERS Sarcoidosis Treatment Guidelines used a rigorous GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology to update treatment recommendations for this condition. This manuscript summarizes the Guideline findings in practical terms for clinicians. Suggested algorithms and treatment dosing recommendations are provided.
The ERS Sarcoidosis Treatment Guidelines addressed the treatment of pulmonary, skin, cardiac, neurologic, and sarcoidosis-associated fatigue. Therapeutic drug dosing and treatment algorithms for these conditions were also addressed. Glucocorticoids were the initial recommended treatment for these conditions except for sarcoidosis-associated fatigue where a pulmonary exercise program or a neurostimulant was initially suggested. Because of the risk of glucocorticoid side-effects, the Guidelines recommended early consideration of glucocorticoid-sparing therapy including certain antimetabolites and two specific tumor necrosis alpha antagonists: infliximab and adalimumab.
The ERS Sarcoidosis Treatment Guidelines used a rigorous GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology to update treatment recommendations for this condition. This manuscript summarizes the Guideline findings in practical terms for clinicians. Suggested algorithms and treatment dosing recommendations are provided.
摘要：
最近,欧洲呼吸学会(ERS)制定了新的结节病治疗国际指南.本手稿试图将ERS结节病治疗指南提炼为易于管理的格式，可供从业人员轻松使用。
ERS结节病治疗指南解决了肺，皮肤,心脏,神经学，和结节病相关的疲劳。还解决了这些病症的治疗药物剂量和治疗算法。糖皮质激素是这些疾病的最初推荐治疗方法，除了结节病相关的疲劳，最初建议使用肺运动计划或神经兴奋剂。由于糖皮质激素副作用的风险，指南建议尽早考虑保留糖皮质激素的治疗,包括某些抗代谢药物和两种特定的肿瘤坏死α拮抗剂:英夫利昔单抗和阿达木单抗.
ERS结节病治疗指南采用了严格的分级(建议分级，评估,开发和评估)方法，以更新针对这种情况的治疗建议。本手稿总结了临床医生实践中的指南发现。提供了建议的算法和治疗剂量建议。
ERS结节病治疗指南解决了肺，皮肤,心脏,神经学，和结节病相关的疲劳。还解决了这些病症的治疗药物剂量和治疗算法。糖皮质激素是这些疾病的最初推荐治疗方法，除了结节病相关的疲劳，最初建议使用肺运动计划或神经兴奋剂。由于糖皮质激素副作用的风险，指南建议尽早考虑保留糖皮质激素的治疗,包括某些抗代谢药物和两种特定的肿瘤坏死α拮抗剂:英夫利昔单抗和阿达木单抗.
ERS结节病治疗指南采用了严格的分级(建议分级，评估,开发和评估)方法，以更新针对这种情况的治疗建议。本手稿总结了临床医生实践中的指南发现。提供了建议的算法和治疗剂量建议。
